caffeine and rifampin
caffeine has been researched along with rifampin in 37 studies
Research
Studies (37)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (8.11) | 18.7374 |
1990's | 4 (10.81) | 18.2507 |
2000's | 9 (24.32) | 29.6817 |
2010's | 18 (48.65) | 24.3611 |
2020's | 3 (8.11) | 2.80 |
Authors
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choo, YM; Doerksen, RJ; Gertsch, J; Hamann, MT; Jacob, MR; Khan, SI; Kudrimoti, S; Madgula, V; Mayer, AM; Odde, S; Peng, J; Pennaka, HK; Prasanna, S; Rao, KV; Tekwani, BL; Tu, LC; Wang, B | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
Myers, DK | 1 |
Gibaldi, M | 1 |
Polk, RE | 1 |
Gillies, NE; Marshall, NJ; Panchapagesan, G | 1 |
Generet, K; Marschall, HU; Matern, S; Wietholtz, H; Zysset, T | 1 |
Gibson, GG; Goldfarb, PS; Gray, TJ; Ogg, MS; Tarbit, M; Williams, JM | 1 |
Arold, G; Bauer, S; Brockmöller, J; Roots, I; Schmider, J | 1 |
Adedoyin, A; Branch, RA; Frye, RF; Romkes, M; Wilson, JW | 1 |
Booker, BM; Brazeau, D; Cloen, D; Frerichs, V; Frye, RF; Haas, CE; Kufel, T; Zaranek, C | 1 |
Backman, JT; Granfors, MT; Neuvonen, PJ | 1 |
Andersson, TB; Bäckström, T; Bertilsson, L; Böttiger, Y; Bredberg, E; Diczfalusy, U; Kanebratt, KP; Sparve, E | 1 |
Abuznait, AH; Burk, D; Cain, C; Ingram, D; Kaddoumi, A | 1 |
Abuznait, AH; Kaddoumi, A; Patrick, SG | 1 |
Abuznait, AH; Hill, RA; Kaddoumi, A; Qosa, H | 1 |
Akamatsu, T; Chida, K; Inui, N; Karayama, M; Namiki, N; Tanaka, S; Uchida, S; Watanabe, H | 1 |
Chang, ZQ; Li, J; Zhai, QQ | 1 |
Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
Hopkins, A; Marshall, JC; Miners, JO; Rowland, A; Sorich, MJ; van Dyk, M; Wood, LS | 1 |
Chakraborty, A; Dhuria, SV; Elmeliegy, M; He, H; Heimbach, T; Huth, F; Ji, Y; Miller, M; Samant, TS; Schiller, H; Umehara, K | 1 |
Aarnoutse, RE; Boeree, MJ; Coenen, MJH; Colbers, A; Dawson, R; Diacon, AH; Fuhr, U; Jager, Vd; Narunsky, K; Padayachee, SD; Phillips, PPJ; Stemkens, R; Svensson, EM; Te Brake, LHM; van Beek, SW | 1 |
Reviews
4 review(s) available for caffeine and rifampin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Drug interactions: Part I.
Topics: Antidepressive Agents, Tricyclic; Caffeine; Cimetidine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Fluconazole; Fluoxetine; Hexobarbital; Humans; Ketoconazole; Nimodipine; Oxidoreductases; Pharmaceutical Preparations; Rifampin; Stereoisomerism; Warfarin; Zidovudine | 1992 |
Drug-drug interactions with ciprofloxacin and other fluoroquinolones.
Topics: Antacids; Caffeine; Ciprofloxacin; Cyclosporins; Drug Interactions; Humans; Intestinal Absorption; Rifampin; Theophylline | 1989 |
Trials
6 trial(s) available for caffeine and rifampin
Article | Year |
---|---|
Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.
Topics: Adult; Alprazolam; Area Under Curve; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Mixed Function Oxygenases; Reference Values; Rifampin | 1999 |
Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.
Topics: Adult; Caffeine; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Gene Expression Regulation, Enzymologic; Humans; Leukocytes, Mononuclear; Male; Midazolam; Omeprazole; Rifampin; RNA, Messenger | 2005 |
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
Topics: Adult; Anti-Bacterial Agents; Blood Pressure; Caffeine; Clonidine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Drug Interactions; Enzyme Induction; Female; Heart Rate; Humans; Male; Rifampin | 2006 |
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.
Topics: Adult; Anti-Ulcer Agents; Antibiotics, Antitubercular; Antihypertensive Agents; Antimalarials; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 Enzyme System; Drug Combinations; Enzyme Induction; Female; Humans; Hydroxycholesterols; Losartan; Male; Middle Aged; Omeprazole; Quinine; Rifampin | 2008 |
Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.
Topics: Adult; Biomarkers; Caffeine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Diet; Genotype; Humans; Male; Midazolam; Phenotype; Racial Groups; Rifampin; Uric Acid; Young Adult | 2019 |
Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Biotransformation; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Labeling; Healthy Volunteers; Humans; Midazolam; Models, Theoretical; Patient Safety; Purines; Rifampin; Risk Assessment; Ritonavir | 2020 |
Other Studies
27 other study(ies) available for caffeine and rifampin
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
Topics: Animals; Anti-Infective Agents; Carbazoles; Cerebellar Diseases; Indole Alkaloids; Mice; Microbial Sensitivity Tests; Molecular Structure; Neurogenic Inflammation; Porifera; Stereoisomerism; Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Inhibition and amplification of the radiation-induced degradation of DNA in Escherichia coli.
Topics: Caffeine; DNA Repair; DNA, Bacterial; Dose-Response Relationship, Radiation; Energy Metabolism; Escherichia coli; Hydrazones; Mutation; Nitriles; Phenylhydrazines; Radiation Effects; Rifampin; Thymidine; Tritium | 1975 |
Rescue by chloramphenicol and rifampicin of UV-irradiated lon, exrA and recA mutants of Escherichia coli K12.
Topics: Caffeine; Cell Survival; Chloramphenicol; Escherichia coli; Methoxsalen; Mutation; Radiation Effects; Rifampin; Ultraviolet Rays | 1973 |
The influence of rifampin treatment on caffeine clearance in healthy man.
Topics: Caffeine; Enzyme Induction; Female; Half-Life; Humans; Male; Microsomes, Liver; Osmolar Concentration; Reference Values; Rifampin | 1995 |
A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro.
Topics: Alkaline Phosphatase; beta-Naphthoflavone; Caffeine; Carbamazepine; Carcinoma, Hepatocellular; Clofibrate; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gene Expression Regulation; Genes, Reporter; Glucocorticoids; Hormone Antagonists; Humans; Isoniazid; Mifepristone; Mixed Function Oxygenases; Phenobarbital; Phenylbutazone; Phenytoin; Receptors, Glucocorticoid; Recombinant Proteins; Rifampin; Tumor Cells, Cultured; Xenobiotics | 1999 |
In vivo modulation of CYP enzymes by quinidine and rifampin.
Topics: Acetylation; Administration, Oral; Adrenergic alpha-Antagonists; Adult; Anti-Arrhythmia Agents; Antibiotics, Antitubercular; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dapsone; Debrisoquin; Drug Administration Schedule; Enzyme Inhibitors; Humans; Male; Mephenytoin; Mixed Function Oxygenases; Quinidine; Reference Values; Rifampin; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Theophylline | 2000 |
Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cell Line; Central Nervous System Agents; Dexamethasone; Estradiol; Humans; Pentylenetetrazole; Phloroglucinol; Rifampin; Staining and Labeling; Terpenes; Up-Regulation; Verapamil | 2011 |
Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cell Line, Tumor; Dexamethasone; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Gene Expression; Humans; Pentylenetetrazole; Pharmaceutical Preparations; Phloroglucinol; Rhodamine 123; Rifampin; Stimulation, Chemical; Terpenes; Up-Regulation; Verapamil | 2011 |
Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease.
Topics: Amyloid beta-Peptides; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Caffeine; Carbon Isotopes; Endothelial Cells; Enzyme Inhibitors; Inulin; Low Density Lipoprotein Receptor-Related Protein-1; Mice; Mice, Inbred C57BL; Microvessels; Peptide Fragments; Receptors, LDL; Rifampin; RNA, Messenger; Tumor Suppressor Proteins; Up-Regulation | 2012 |
Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.
Topics: Adult; Antibiotics, Antitubercular; Asian People; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Imidazoles; Losartan; Male; Midazolam; Omeprazole; Rifampin; Tetrazoles; Theophylline; Time Factors; Withholding Treatment | 2013 |
Evaluation on activity of cytochrome p450 enzymes in turbot via a probe drug cocktail.
Topics: Animals; Antitubercular Agents; Area Under Curve; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Dapsone; Enzyme Induction; Flatfishes; Folic Acid Antagonists; Muscle Relaxants, Central; Nucleic Acid Synthesis Inhibitors; Phosphodiesterase Inhibitors; Rifampin | 2014 |
Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
Topics: Administration, Intravenous; Aging; Animals; Caffeine; Callithrix; Cytochrome P-450 CYP2C19; Genotype; Humans; Male; Metoprolol; Midazolam; Omeprazole; Rifampin; Substrate Specificity; Warfarin | 2018 |
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Humans; Midazolam; Omeprazole; Rifampin; Tolbutamide; Tuberculosis, Pulmonary | 2023 |